menu search

Scynexis (scyx) inks antifungal drug deal with gsk

Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also contin...

March 31, 2023, 1:47 pm

Avidity (rna) down on update from neuromuscular disease study

Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC ...

March 31, 2023, 1:04 pm

Ibio advances anti-ccr8 antibody program to preclinical in vivo testing

– Immuno-oncology candidate discovered using iBio’s AI epitope steering platform – – Expands Tr...

March 31, 2023, 12:10 pm

Scynexis: licensing deal with gsk, upgrading to a hold rating from a sell

GSK and SCYNEXIS signed an exclusive licensing agreement for Brexafemme, an FDA-approved medicine for vulvovaginal ...

March 31, 2023, 11:47 am

Why biomea fusion stock crushed it this week

Tuesday, Biomea Fusion announced encouraging mid-stage trial results for its type 2 diabetes candidate....

March 30, 2023, 2:35 pm

7 short-squeeze stocks that could explode in april

While an extremely risky proposition, short-squeeze stocks – as meme traders demonstrated – can occasionally yield radical profitability. However,...

March 30, 2023, 2:07 pm

Catalent (ctlt) new launch to aid tpd programs, clinical trials

Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD ...

March 30, 2023, 1:42 pm

Why is scynexis (scyx) stock up 69% today?

Scynexis (NASDAQ: SCYX ) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme. Brexafemme is an ...

March 30, 2023, 10:26 am

Valneva to present on its chikungunya vaccine candidate and host a roundtable at the 23rd world vaccine congress in washington d.c.

Saint Herblain (France), March 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today it will prese...

March 30, 2023, 1:00 am

Valneva q4: resilient pipeline and partnership with pfizer, reinforcing a promising future

Valneva's pipeline and high-stakes clinical catalysts warrant a buy rating, despite the setback in its Lyme disease Phase 3 trial. The CHIKV vaccine <...

March 29, 2023, 10:56 pm

Cardiol therapeutics offers an update on operations as it advances the development of its lead drug candidate cardiolrx

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc CEO David Elsley told investors in a year-end 2022 update on operations that the life sciences compan...

March 29, 2023, 5:11 pm

Bioxytran's positive phase 2 trial results featured in ‘vaccines' peer-reviewed journal

Bioxytran said positive top-line safety and efficacy results from the company's randomized, placebo-controlled Phase 2 clinical trial of its drug ...

March 29, 2023, 4:04 pm

Biomea (bmea) up 99% on upbeat data from type ii diabetes study

Preliminary data from an ongoing mid-stage study shows that treatment with Biomea's (BMEA) lead candida...

March 29, 2023, 1:46 pm

Betterlife pharma says betr-001 drug candidate featured in drug discovery & development article

BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) has announced that an article titled “Non-hallucinogenic LSD derivative reduces depression symptoms in...

March 29, 2023, 9:31 am

Carl icahn wants to bring illumina's old ceo back

The billionaire activist, who has launched a proxy battle at Illumina, wants change at the management level too, and he has a ...

March 29, 2023, 7:32 am

Bristol myers (bmy) gets approval of psoriasis drug in eu

Bristol Myers' (BMY) Sotyktu gets approval from the European Commission to treat adults with moderate-to-severe plaque psoriasis who are ...

March 28, 2023, 4:45 pm

Viking therapeutics shares up more than 50% on positive trial results for obesity drug

Viking Therapeutics (NASDAQ:VKTX) shares had added more than 55% on Tuesday after the biopharmaceutical company published positive early-stage data fo...

March 28, 2023, 10:51 am

Iovance (iova) completes rolling bla filing for melanoma drug

Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indic...

March 27, 2023, 12:59 pm

Elliott backs down on plan to nominate rival salesforce board candidates

Elliott Investment Management no longer intends to nominate a rival slate of directors to Salesforce Inc.'s CRM, +1.40% board, according to a new stat...

March 27, 2023, 7:02 am

Aclaris therapeutics to participate in the h.c. wainwright autoimmune & inflammatory disease virtual conference

WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on develo...

March 27, 2023, 7:00 am


Search within

Pages Search Results: